What Boston’s Life Sciences Community is Taking for Granted

I spent an enlightening week in Tokyo earlier this month participating in the Kauffman Fellows Japan Summit. This summit was the brainchild of three visionary Kauffman Fellows who are on a mission to instill entrepreneurship into the Japanese culture. During the three days we heard about the current (dismal) status of venture capital and entrepreneurial success in Japan—especially in the life sciences—in contrast to the unbelievable track record of Japanese engineering and precision manufacturing, as well as the country’s output of patents, which rivals that of the U.S.

Walking around Tokyo and interacting with the many smart minds at the summit, I had to scratch my head—at first blush, the ingredients of great entrepreneurship in life sciences are there. But why is there no soup? One of the most staggering statistics presented at the meeting was that just $200M was invested in local life science companies in 2008, with one pharma spin-out venture taking half the total!

And then it started to sink in how privileged we are in the Boston area, where the next successful or aspiring entrepreneur, scientist, engineer, venture capitalist, IP or venture lawyer, skilled technician, teaching hospital, pharmaceutical company, or device company is just a door away. We are steeped in this culture of entrepreneurship and have been so for many years now. This Boston life science ecotope is as unique as Silicon Valley is for the techies, and it behooves us to make sure we take full advantage of this incredible competitive edge.

People outside of our unique Boston ecotope understand how powerful our “soup” is—Japanese investors searching for attractive opportunities in private equity and venture capital are looking first to the U.S., then checking out Europe and China, only to search their own home market last. How discouraging that must be for the few life sciences pioneers in Japan! I will make it a habit now to remind folks in our industry, as well as local government officials, that we should cherish what we have and work hard to keep things intact and healthy.

Author: Jens Eckstein

Jens Eckstein joined TVM Capital in 2004 and is a general partner in the firm’s life sciences practice, where he focuses on earlier-stage investments. He is a member of the Board of Directors of CoNCERT Pharmaceuticals, Magen Biosciences, and Ascent Therapeutics, and served as an Advisor to Sirtris Pharmaceuticals. As director, Lead Discovery and Research IT, at Enanta Pharmaceuticals, he directed the company's lead discovery and knowledge management programs for novel therapeutics in hepatitis, asthma, psoriasis, and other autoimmune disorders. Prior to joining Enanta, Dr. Eckstein managed research groups in biochemistry, structural biology, and computational chemistry at Mitotix (now GPC-Biotech). Dr. Eckstein earned his doctorate, summa cum laude, in biological chemistry at the University of Konstanz and Harvard University. He was a postdoctoral fellow at the University of California in San Francisco and is an alumnus of the Kauffman Fellows Program. The author of more than 20 scientific publications, Dr. Eckstein also holds several issued and pending patents. He is managing editor of Frontiers in Bioscience “Current Topics in Lead Discovery” and serves as an editorial board advisor for IDrugs. Dr. Eckstein is also an Advisor to the Alzheimer Research Forum (ARF) and a founding member of the Cure Dystonia Initiative Advisory Council (CDIAC).